Jump to content

Mef2

From Wikipedia, the free encyclopedia
(Redirected from Myocyte Enhancer Factor)
Dimeric structure of the MADS (red) and MEF2 (green) domains of the human MEF2B transcription factor complexed with DNA (orange) based on the PDB: 1N6J​ crystallographic coordinates.
The domain organization and sequence comparison of Mef2 proteins from representative species.[1] The amino acid numbering shown is of the human MEF2A sequence and the per cent sequence identities are all relative to hMEF2A. The three domain, MADS (red), MEF2 (green), and transactivation domains (TAD; cyan) are each highlighted in a different color.

In the field of molecular biology, myocyte enhancer factor-2 (Mef2) proteins are a family of transcription factors which through control of gene expression are important regulators of cellular differentiation and consequently play a critical role in embryonic development.[1] In adult organisms, Mef2 proteins mediate the stress response in some tissues.[1] Mef2 proteins contain both MADS-box and Mef2 DNA-binding domains.

Discovery

[edit]

Mef2 was originally identified as a transcription factor complex through promoter analysis of the muscle creatine kinase (mck) gene to identify nuclear factors interacting with the mck enhancer region during muscle differentiation.[2] Three human mRNA coding sequences designated RSRF (Related to Serum Response Factor) were cloned and shown to dimerize, bind a consensus sequence similar to the one present in the MCK enhancer region, and drive transcription.[3] RSRFs were subsequently demonstrated to encode human genes now named Mef2A, Mef2B and Mef2D.

Species distribution

[edit]

The Mef2 gene is widely expressed in all branches of eukaryotes from yeast to humans. While Drosophila has a single Mef2 gene, vertebrates have at least four versions of the Mef2 gene (human versions are denoted as MEF2A, MEF2B, MEF2C, and MEF2D), all expressed in distinct but overlapping patterns during embryogenesis through adulthood.[4]

Sequence and structure

[edit]

All of the mammalian Mef2 genes share approximately 50% overall amino acid identity and about 95% similarity throughout the highly conserved N-terminal MADS-box and Mef2 domains, however their sequences diverge in their C-terminal transactivation domain (see figure to the right).[5]

The MADS-box serves as the minimal DNA-binding domain, however an adjacent 29-amino acid extension called the Mef2 domain is required for high affinity DNA-binding and dimerization. Through an interaction with the MADS-box, Mef2 transcription factors have the ability to homo- and heterodimerize,[6] and a classic nuclear localization sequence (NLS) in the C-terminus of Mef2A, -C, and – D ensures nuclear localization of the protein.[7] D-Mef2 and human MEF2B lack this conserved NLS but are still found in the nucleus.[8]

Function

[edit]

Development

[edit]

In Drosophila, Mef2 regulates muscle development.[9] Mammalian Mef2 can cooperate with bHLH transcription factors to turn non-muscle cells in culture into muscle.[10] bHLH factors can activate Mef2c expression, which then acts to maintain its own expression.[11]

Loss of Mef2c in neural crest cells results in craniofacial defects in the developing embryo and neonatal death caused by blocking of the upper airway passages.[12][13] Mef2c upregulates the expression of the homeodomain transcription factors DLX5 and DLX6, two transcription factors that are necessary for craniofacial development.[12][13]

Stress response

[edit]

In adult tissues, Mef2 proteins regulate the stress-response during cardiac hypertrophy[14] and tissue remodeling in cardiac and skeletal muscle.[15]

Cardiovascular system

[edit]

Mef2 is a critical regulator in heart development and cardiac gene expression.[16] In vertebrates, there are four genes in the Mef2 transcription factor family: Mef2a, Mef2b, Mef2c, and Mef2d. Each is expressed at specific times during development. Mef2c, the first gene to be expressed in the heart, is necessary for the development of the anterior (secondary) heart field (AHF), which helps to form components of the cardiac outflow tract and most of the right ventricle.[17][18] In addition, Mef2 genes are indicated in activating gene expression to aid in sprouting angiogenesis, the formation of new blood vessels from existing vessels.[19]

Knockout studies

[edit]

In mice, knockout studies of Mef2c have demonstrated that crucial role that it plays in heart development. Mice without the Mef2c die during embryonic day 9.5–10 with major heart defects, including improper looping, outflow tract abnormalities, and complete lack of the right ventricle.[16] This indicates improper differentiation of the anterior heart field. When Mef2c is knocked out specifically in the AHF, the mice die at birth with a range of outflow tract defects and severe cyanosis. Thus, Mef2 is necessary for many aspects of heart development, specifically by regulating the anterior heart field.[20]

Additional Information

[edit]

MEF2, Myocyte Enhancer Factor 2, is a transcription factor with four specific numbers such as MEF2A, B, C, and D. Each MEF2 gene is located on a specific chromosome. MEF2 is known to be involved in the development and the looping of the heart (Chen) MEF2 is necessary for myocyte differentiation and gene activation (Black). Both roles contribute to the heart structure, and if there is a disruption with MEF2 in embryonic development, it can lead to two phenotypic problems (Karamboulas). The Type-I phenotype can cause severe malformations to the heart and the type-II phenotype, while it looks normal, has a thin-walled myocardium which can cause cardiac insufficiency. Another problem that can arise is from the knockout gene MEF2C. MEF2C is known to be directly related to congenital heart disease when associated with Tdgf1 (teratocarcinoma-derived growth factor 1). If MEF2C improperly regulates Tdgf1, developmental defects arise, especially within the embryonic development of the heart. (Chen). The way that MEF2C interacts with the protein Tdgf1 is through the 〖Ca〗^(2+) signaling pathway, which is required to regulate different mechanisms. MicroRNA's, non-small coding RNAs, also play a specific role in regulating MEF2C. The expression of congenital heart disease is upregulated due to the downregulation of the microRNA miR-29C (Chen). A few other known diseases associated with the MEF2 family are liver fibrosis, cancers, and neurodegenerative diseases (Chen).

References

[edit]
  1. ^ a b c Potthoff MJ, Olson EN (December 2007). "MEF2: a central regulator of diverse developmental programs". Development. 134 (23): 4131–40. doi:10.1242/dev.008367. PMID 17959722. S2CID 27125540.
  2. ^ Gossett LA, Kelvin DJ, Sternberg EA, Olson EN (1 November 1989). "A new myocyte-specific enhancer-binding factor that recognizes a conserved element associated with multiple muscle-specific genes". Mol. Cell. Biol. 9 (11): 5022–33. doi:10.1128/MCB.9.11.5022. PMC 363654. PMID 2601707.
  3. ^ Pollock R, Treisman R (1991). "Human SRF-related proteins: DNA-binding properties and potential regulatory targets". Genes Dev. 5 (12a): 2327–41. doi:10.1101/gad.5.12a.2327. PMID 1748287.
  4. ^ McKinsey TA, Zhang CL, Olson EN (2002). "MEF2: a calcium-dependent regulator of cell division, differentiation and death". Trends Biochem. Sci. 27 (1): 40–7. doi:10.1016/S0968-0004(01)02031-X. PMID 11796223.
  5. ^ Black BL, Olson EN (1998). "Transcriptional control of muscle development by myocyte enhancer factor-2 (MEF2) proteins". Annu Rev Cell Dev Biol. 14: 167–96. doi:10.1146/annurev.cellbio.14.1.167. PMID 9891782.
  6. ^ Molkentin JD, Olson EN (1996). "Combinatorial control of muscle development by basic helix-loop-helix and MADS-box transcription factors". Proc Natl Acad Sci USA. 93 (18): 9366–73. Bibcode:1996PNAS...93.9366M. doi:10.1073/pnas.93.18.9366. PMC 38433. PMID 8790335.
  7. ^ Borghi S, Molinari S, Razzini G, Parise F, Battini R, Ferrari S (2001). "The nuclear localization domain of the Mef2 family of transcription factors shows member-specific features and mediates the nuclear import of histone deacetylase 4". J Cell Sci. 114 (Pt 24): 4477–83. doi:10.1242/jcs.114.24.4477. PMID 11792813.
  8. ^ Yu YT (1996). "Distinct domains of myocyte enhancer binding factor-2A determining nuclear localization and cell type-specific transcriptional activity". J Biol Chem. 271 (40): 24675–83. doi:10.1016/S0021-9258(18)40058-0. PMID 8798735. S2CID 25878690.
  9. ^ Lilly B, Galewsky S, Firulli AB, Schulz RA, Olson EN (June 1994). "D-MEF2: a MADS box transcription factor expressed in differentiating mesoderm and muscle cell lineages during Drosophila embryogenesis". Proc. Natl. Acad. Sci. U.S.A. 91 (12): 5662–6. Bibcode:1994PNAS...91.5662L. doi:10.1073/pnas.91.12.5662. PMC 44056. PMID 8202544.
  10. ^ Molkentin JD, Black BL, Martin JF, Olson EN (December 1995). "Cooperative activation of muscle gene expression by MEF2 and myogenic bHLH proteins". Cell. 83 (7): 1125–36. doi:10.1016/0092-8674(95)90139-6. PMID 8548800. S2CID 14140159.
  11. ^ Wang DZ, Valdez MR, McAnally J, Richardson J, Olson EN (November 2001). "The Mef2c gene is a direct transcriptional target of myogenic bHLH and MEF2 proteins during skeletal muscle development". Development. 128 (22): 4623–33. doi:10.1242/dev.128.22.4623. PMID 11714687.
  12. ^ a b Verzi MP, Agarwal P, Brown C, McCulley DJ, Schwarz JJ, Black BL (April 2007). "The transcription factor MEF2C is required for craniofacial development". Dev. Cell. 12 (4): 645–52. doi:10.1016/j.devcel.2007.03.007. PMC 1920108. PMID 17420000.
  13. ^ a b Miller CT, Swartz ME, Khuu PA, Walker MB, Eberhart JK, Kimmel CB (August 2007). "mef2ca is required in cranial neural crest to effect Endothelin1 signaling in zebrafish". Dev. Biol. 308 (1): 144–57. doi:10.1016/j.ydbio.2007.05.018. PMC 2148033. PMID 17574232.
  14. ^ Zhang CL, McKinsey TA, Chang S, Antos CL, Hill JA, Olson EN (August 2002). "Class II histone deacetylases act as signal-responsive repressors of cardiac hypertrophy". Cell. 110 (4): 479–88. doi:10.1016/S0092-8674(02)00861-9. PMC 4459650. PMID 12202037.
  15. ^ Potthoff MJ, Wu H, Arnold MA, Shelton JM, Backs J, McAnally J, Richardson JA, Bassel-Duby R, Olson EN (September 2007). "Histone deacetylase degradation and MEF2 activation promote the formation of slow-twitch myofibers". J. Clin. Invest. 117 (9): 2459–67. doi:10.1172/JCI31960. PMC 1957540. PMID 17786239.
  16. ^ a b Anderson CM, Hu J, Thomas R, Gainous B, Celona B, Sinha T, Dickel DE, Heidt AB, Xu SM, Bruneau BG, Pollard KS, Pennacchio LA, Black BL (2017). "Cooperative activation of cardiac transcription through myocardin bridging of paired MEF2 sites". Development. 144 (7): 1234–1241. doi:10.1242/dev.138487. PMC 5399617. PMID 28351867.
  17. ^ . Barnes RM, Harris IS, Jaehnig EJ, Sauls K, Sinha T, Rojas A, Schachterle W, McCulley DJ, Norris RA, Black BL. (January 2016). "Mef2c regulates outflow tract alignment and transcriptional control of Tdgf1." Development. 143: 774-779. oi:10.1242/dev.126383
  18. ^ Verzi MP, McCulley DJ, De Val S, Dodou E, Black BL (2005). "The right ventricle, outflow tract, and ventricular septum comprise a restricted expression domain within the secondary/anterior heart field". Developmental Biology. 287 (1): 134–145. doi:10.1016/j.ydbio.2005.08.041. PMID 16188249.
  19. ^ Sacilotto N, Chouliaras KM, Nikitenko LL, Lu YW, Fritzsche M, Wallace MD, Nornes S, Garcia-Moreno F, Payne S, Bridges E, Liu K, Biggs D, Ratnayaka I, Herbert SP, Molnar Z, Harris AL, Davies B, Bond GL, Bou-Gharios G, Shwarz JJ, De Val S (2016). "MEF2 transcription factors are key regulators of sprouting angiogenesis". Genes Dev. 30 (20): 2297–2309. doi:10.1101/gad.290619.116. PMC 5110996. PMID 27898394.
  20. ^ Barnes RM, Harris IS, Jaehnig EJ, Sauls K, Sinha T, Rojas A, Schachterle W, McCulley DJ, Norris RA, Black BL. (January 2016). "Mef2c regulates outflow tract alignment and transcriptional control of Tdgf1." Development. 143: 774-779. oi:10.1242/dev.126383

Black, Brian L., and Richard M. Cripps. “Myocyte Enhancer Factor 2 Transcription Factors in Heart Development and Disease.” Heart Development and Regeneration, 2010, pp. 673–699., doi:10.1016/b978-0-12-381332-9.00030-x.

Chen, Xiao, et al. “MEF2 Signaling and Human Diseases.” Oncotarget, vol. 8, no. 67, 2017, pp. 112152–112165., doi:10.18632/oncotarget.22899.

Karamboulas, C., et al. “Disruption of MEF2 Activity in Cardiomyoblasts Inhibits Cardiomyogenesis.” Journal of Cell Science, vol. 120, no. 1, 2006, pp. 4315–4318., doi:10.1242/jcs.03369.

[edit]
Retrieved from "https://en.wikipedia.org/w/index.php?title=Mef2&oldid=1187489352"